A composition for topical application to the skin for alleviation or prevention of dry flaky skin condition, dandruff or acne comprising stratum corneum chymotrypsin-like enzyme. The composition may additionally comprise a second enzyme selected from glycosidases, other proteases, lipases and mixtures thereof.

(S)- alpha -phenyl-2-pyridineethanamine, and its pharmaceutically acceptable derivatives, are useful in the treatment of neurodegenerative disorders, and exhibit linear pharmacokinetics.

A support carrying a homocyclic or heterocyclic ring containing a first and second carbon atom wherein: (i) the first carbon atom is substituted by a nucleophilic group or a group convertible to a nucleophilic group on treatment with base; (ii) the second carbon atom is substituted by a hydroxy group, a hydroxy group protected by an acid labile protecting group, or a phosphate group substituted by...

PCT No. PCT/GB93/00706 Sec. 371 Date Nov. 4, 1993 Sec. 102(e) Date Nov. 4, 1993 PCT Filed Apr. 5, 1993 PCT Pub. No. WO93/20047 PCT Pub. Date Oct. 14, 1993.Hydroxamic acid derivatives of formula (I): an (C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, phenyl, substituted phenyl, phenyl(C1-C6)alkyl, heterocyclyl, (C1-C6)alkylcarbonyl, phenacyl or substituted phenacyl group; R2 represents hydrogen o...

Compounds of general formula (II) wherein R<3> is C1-35 hydrocarbyl group optionally substituted by one to five substituents, selected from halo, C1-6alkoxy, hydroxy, amino, and mono- or di-C1-4alkyl-amino; and either the dotted line represents a double bond between the 2 and 3 positions of the naphthyl ring; R<1> and R<4> each represent = O; and R<2> represents a group (a) wherein n is 2 or 3, R<...

PCT No. PCT/GB93/00716 Sec. 371 Date Jan. 5, 1995 Sec. 102(e) Date Jan. 5, 1995 PCT Filed Apr. 6, 1993 PCT Pub. No. WO93/19781 PCT Pub. Date Oct. 14, 1993Non-ionic surfactant vesicles (NSIV) with entrapped antigen act as potent immunological adjuvants and can produce antibody titers of the same order of magnitude as those using Freund's Complete Adjuvant. The invention provides vaccines comprising...

PCT No. PCT/GB93/00729 Sec. 371 Date Oct. 6, 1994 Sec. 102(e) Date Oct. 6, 1994 PCT Filed Apr. 7, 1993 PCT Pub. No. WO93/20034 PCT Pub. Date Oct. 14, 1993.An aldolisation-dehydration process is disclosed for converting an aldehyde, e.g. n-valeraldehyde, to a substituted acrolein, e.g. propyl butyl acrolein (2-propylhept-2-enal). Aldolisation and dehydration are effected in a stirred tank reactor (...

PCT No. PCT/NL93/00070 Sec. 371 Date Jan. 9, 1995 Sec. 102(e) Date Jan. 9, 1995 PCT Filed Mar. 25, 1993 PCT Pub. No. WO93/20050 PCT Pub. Date Oct. 14, 1993.The invention relates to novel bis-iminoazacyclo pentane polyols according to the formula given below, wherein R1=H, alkyl or R4, whereby R4 is OH, hydroxyalkyl, hydroxyaryl or hydroxyaralkyl and R2 and R3 are independently of one another, OH, ...

This invention relates to certain hydroxy derivatives of 3,4-dihydro-2,5,7,8-tetraalkyl-2H-1-benzopyran-2-carboxylic acids and the lactones thereof, to the processes and intermediates useful for their preparation and to their use as free radical scavengers useful in the treatment of tissue damage implicated with free oxygen radicals.

PCT No. PCT/US93/02289 Sec. 371 Date Sep. 26, 1994 Sec. 102(e) Date Sep. 26, 1994 PCT Filed Mar. 22, 1993 PCT Pub. No. WO93/20063 PCT Pub. Date Oct. 14, 1993Disclosed is a compound of Formula 1.0: (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: AR1 represents AR2 represents or a five-membered heterocyclic aromatic group selected from th...

PCT No. PCT/US93/02418 Sec. 371 Date Sep. 23, 1994 Sec. 102(e) Date Sep. 23, 1994 PCT Filed Mar. 24, 1993 PCT Pub. No. WO93/20080 PCT Pub. Date Oct. 14, 1993The invention is drawn to bridged bis-aryl carbinol compounds of formula (I): (I) wherein, a, b, c, d, Q, Z, L and R1-R9 are as defined in the specification, their pharmaceutical composition and method of using them in treating as...

Quinazoline compounds which demonstrate antiproliferative activity, such as antitumor activity, processes of preparing these compounds, pharmaceutical compositions containing these compounds, and the use of these compounds. These compounds inhibit the growth and proliferation of the cells of higher organisms and microorganisms, such as bacteria, yeasts and fungi. Preferred quinazoline compounds ar...

A process for the conversion of cyclohexyl hydroperoxide to cyclohexanone and cyclohexanol by turbulent high-intensity mixing with aqueous caustic containing a metal salt that accelerates the decomposition of cyclohexyl hydroperoxide.

Azeotropic or azeotrope-like compositions of effective amounts of 1,1,2,2,3,3,4,4-octafluorobutane and trans-1,2-dichloroethylene; cis-1,2-dichloroethylene; or 1,1-dichloroethane to form an azeotropic or azeotrope-like composition are disclosed that are useful as cleaning agents, refrigerants, aerosol propellants, heat transfer media, gaseous dielectrics, fire extinguishing agents, expansion agent...

Invented are pharmaceutical compositions containing N-t-butyl-androst-3,5-diene-17 beta -carboxamide)-3-carboxylic acid or a salt thereof or 17 beta -(N-t-butylcarboxamide-estra-1,3,5(10)-triene-3-carboxylic acid or a salt thereof and an alpha-adrenergic receptor antagonist compound, and methods of using these compositions to treat benign prostatic hypertrophy.

A class of organosilanes of the general formula wherein Ar is a divalent aromatic radical; Rf is a defined fluoroalkyl or perfluoroalkyl ether group; X is methyl, Rf Ar as defined above, a halogen other than fluorine, or an alkoxy group; and each one of Y and Z is a halogen other than fluorine or an alkoxy group. These organosilanes are very useful as precursors to polysiloxane couplin...

This invention concerns inhibiting tooth enamel demineralization by using a water soluble phosphate, particularly a pyrophosphate or tripolyphosphate, to inhibit demineralization while not negatively impacting remineralization.

Compounds having the formula I: I are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

PCT No. PCT/EP93/00738 Sec. 371 Date Oct. 6, 1994 Sec. 102(e) Date Oct. 6, 1994 PCT Filed Mar. 25, 1993 PCT Pub. No. WO93/21177 PCT Pub. Date Oct. 28, 1993 (I) Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 is a substituted alkylene; C3-C7 cycloalkyl optionally substituted with HO; C3-C6 alkenyl optionally substituted with aryl; C5-C7 cycloalkenyl; o...

PCT No. PCT/EP93/00791 Sec. 371 Date Sep. 15, 1994 Sec. 102(e) Date Sep. 15, 1994 PCT Filed Apr. 1, 1993 PCT Pub. No. WO93/21196 PCT Pub. Date Oct. 28, 1993The preparation of alkyl glycosides by reaction of aqueous glycoses having a water content of 10-80% by weight with aliphatic primary alcohols having from 5 to 30 C atoms is described, in which (a) the alcohols and the glycoses are employed in ...